首页 | 本学科首页   官方微博 | 高级检索  
检索        

双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗慢性腹泻的疗效及安全性分析
引用本文:伍晓剑.双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗慢性腹泻的疗效及安全性分析[J].中国现代药物应用,2014(1):5-7.
作者姓名:伍晓剑
作者单位:东莞市虎门医院内科,523903
摘    要:目的探讨双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗慢性腹泻的疗效及安全性。方法将80例慢性腹泻患者按照抽签方法随机地均分为对照组与观察组,各为40例。对照组给予常规治疗,观察组在此基础上给予双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗。比较两组临床疗效、腹泻缓解时间、粪便形状变化情况、粪检结果及不良反应发生率。结果①对照组临床治疗总有效率为72.50%,显著低于观察组(95.00%)(P〈0.05);②两组腹泻缓解时间、粪便成形及糊状便相比,差异均具有统计学意义(P〈0.05);③两组患者杆球比例倒置、细菌计数减少及真菌感染相比,差异均具有统计学意义(P〈0.05,P〈0.01);④两组不良反应发生率相比,差异无统计学意义(P〉0.05)。结论双歧杆菌、肠球菌、乳杆菌和芽孢杆菌四联活菌肠溶胶囊治疗慢性腹泻的疗效显著,安全性相对较高,值得在临床上加以推广及应用。

关 键 词:四联活菌肠溶胶囊  慢性腹泻  疗效  安全性

Efficacy and safety analysis of bifidobacterium,lactobacillus, enterococcus,bacillus tetravaccine enter-ic-coated capsules in the treatment of chronic diarrhea
Institution:WU Xiao-fian. Department of Internal Medicine, Humen Hospital, Dongguan 523903, China
Abstract:Objective To investigate the efficacy and safety of bifidobacterium, lactobacillus, entero- coccus, bacillus tetravaccine enteric-coated capsules in treatment of chronic diarrhea. Methods 80 cases of patients with chronic diarrhea by balloting randomly were divided into control group and observation group, 40 cases for each group. The control group received conventional therapy, on the basis of the observation group giv- en bifidobacterium, enterococcus, bacillus and lactobaciUus tetravaccine enteric-coated capsules treatment. Comparative clinical efficacy, diarrhea relief time, changes in the shape of feces, fecal examination results and the incidence of adverse reactions. Results ① control group, clinical total effective rate was 72.50%, signifi- cantly lower than the observation group (95.00%) ( P 〈 0. 05 ) ; ② two sets of diarrhea relief time, feces form- ing and paste it, the difference was statistically significant ( P 〈 0. 05 ) ; ③ the proportion of patients were invert- ed rod ball, reducing bacterial counts and fungal infections, the differences were statistically significant (P 〈 0. 05, P 〈0. 01 ) ; ④ incidence of adverse reactions compared the two groups, the difference was not statistical- ly significant ( P 〉 0.05 ). Conclusion Bifidobacterium, enterococcus, lactobaciUus, bacillus tetravaccine enteric-coated capsules in treatment of chronic diarrhea has a significant effect, the security is relatively high, it is worth to be promoted in clinical practice and application.
Keywords:Tetravaecine enteric-coated capsules  Chronic diarrhea  Efficacy  safety
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号